



Da Volterra Appoints Khoso Baluch and Nabil Abadir to its Board of Directors

- **Two senior pharma executives with a long-standing international experience and know-how in the pharmaceutical and biotechnology industry join Da Volterra's Board of Directors**
- **Khoso Baluch becomes Chairman of the Board of Da Volterra**

Paris (France), December 17, 2021 – Da Volterra, a late-stage biopharmaceutical company developing novel intestinal microbiome-protective therapies, announced today the appointment of two senior pharma executives: Khoso Baluch, as Independent Chairman of the Board, and Dr. Nabil Abadir as Independent Board Member. They will further strengthen the Board of Directors by providing their broad expertise in advancing novel therapeutics from discovery towards commercialization at a global scale.

Khoso Baluch has over 36 years of experience across global geographies, most recently as CEO and Board member of CorMedix Inc., a publicly-traded US company. Prior to joining CorMedix Inc., Khoso worked for 8 years for the global biopharmaceutical company UCB, notably as Senior Vice President & President European Region. He also worked for Eli Lilly & Co for 24 years, holding international positions spanning Europe, the Middle East and the United States in General Management, Business Development, Market Access and Product leadership. Khoso is currently a Board member at Poxel Pharma, a French publicly traded Biotech company. He also sits on the Strategic Advisory Committee for Morningside Biopharma Advisory. Skilled at building strategic partnerships and driving market entry and expansion, Khoso successfully led U.S. and international commercial teams in primary care, specialty, and hospital segments.

Dr. Nabil Abadir is a Medical Doctor with over 25 years of experience in executive positions in the biotechnology and pharmaceutical industry (Clementia Pharmaceuticals Inc., acquired by IPSEN, Ferring Pharma, Novartis, Sanofi, Abbott, Schering Plough and Merck). Throughout his career he successfully led, built and strengthened a number of medical organizations at the local, regional and global level: he created multiple best practices, SOPs, guidelines, asset life cycles, real-life data generation and dissemination plans including Health Economic data to support the pricing and reimbursement of various assets. His extensive experience covers a wide range of therapy areas, including oncology and anti-infectives. He also experienced a number of acquisitions and mergers and participated in multiple business development deals. Nabil is a strong believer in the importance of data generation and dissemination, education and building a solid network with the scientific community and external stakeholders to ensure the best management and safety of patients as the first and foremost priority.

"I am delighted to welcome Khoso Baluch and Nabil Abadir to Da Volterra's Board of Directors. With their high level and international leadership experiences in the pharmaceutical and biotechnology industry, notably in the US, they will provide valuable input and guidance to the development of Da Volterra as we move towards the final stage of our clinical plan and the commercialization of our first product.", said Florence Séjourné, Da Volterra's Chief Executive Officer.

Khoso Baluch commented on his appointment: *"It is an honor to be invited to be Chairman of the Board of Da Volterra, a truly exciting biotech company that has the potential to revolutionize the way we treat cancer and its related complications through novel microbiome therapies. I look forward to working*

with the outstanding team already in place to guide and support the development of the company and its exciting pipeline!”. Dr. Nabil Abadir stated: “I am very impressed by the dedication of the Da Volterra team and the key milestones already achieved with DAV132. I am glad to work alongside the team to further enhance the value of microbiome protective therapies and the commercial opportunity”.

About Da Volterra

Headquartered in Paris (France), Da Volterra is a clinical-stage biopharmaceutical company developing innovative products to prevent intestinal microbiome dysbiosis in patients with cancer.

The company’s lead product-candidate, DAV132, is the world’s most advanced product protecting against the clinical consequences of microbiome dysbiosis: it is a unique and first-in-class product designed to inactivate antibiotics and some chemotherapies as they reach the colon and prevent them from disrupting the intestinal microbiome.

To date, 496 human subjects have received DAV132 in [six Phase 1 and one Phase 2 clinical trials](#). The recent success of the Phase 2 SHIELD study has shown that DAV132 is safe for use in hospitalized elderly patients with several comorbidities and taking concomitant medications, and is able to protect the intestinal microbiome from antibiotic damage.

Preventing microbiome disruption is an important and largely unmet medical need in particular in patients with cancer. It is expected to prevent life-threatening complications such as severe infections and graft-versus-host disease in patients with hematologic malignancies, increase response to immunotherapies in cancer patients taking antibiotics, and prevent chemotherapy-induced severe diarrhea leading to dose reduction or discontinuation. DAV132 is thus expected to significantly increase the survival of patients with cancer.

For more information on Da Volterra and DAV132, visit <https://davalterra.com/>.

Contact

Florence Séjourné, Chief Executive Officer of Da Volterra
+33 1 58 39 32 20 – press@davalterra.com